RxDoctor Payments Data

Aseedu Kalik, MD

Internal Medicine · Owensboro, KYNPI 1659320794

Payments from drug & device makers

$1,006in general payments, 2019–2025

Across 78 payments — averaging $12.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$229
  • Amarin Pharma, Inc.$201
  • Astellas Pharma US Inc$175
  • Sunovion Pharmaceuticals Inc.$145
  • AbbVie$136
  • GSK$31
  • plus $90 from 5 others

What the payments were for

  • Food & beverage$58858%
  • Education$41842%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,006 in reported general payments places this provider in the 65th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$168,411
Medicare patients
394
Services billed
10,316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide123$150,691
OzempicSemaglutide151$144,336
JardianceEmpagliflozin159$108,333
Enbrel SureclickEtanercept11$82,477
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl668$49,083
MounjaroTirzepatide48$48,296
TrulicityDulaglutide37$45,159
Teriparatide12$42,729
EliquisApixaban49$41,739
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog54$32,629
Breztri AerosphereBudesonide/Glycopyr/Formoterol47$31,356
FarxigaDapagliflozin Propanediol33$30,239
EntrestoSacubitril/Valsartan44$28,333
GemtesaVibegron38$20,726
Lantus SolostarInsulin Glargine,hum.Rec.Anlog128$19,596

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$12$93,45585 claims
NovartisEntresto$229$28,33344 claims
AbbVieLinzess$136$16,71722 claims
GSKAnoro Ellipta$31$14,24532 claims
Astellas Pharma US IncMyrbetriq$175$8,21712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Owensboro

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →